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ABSTRACT Objective: Germline mutations in mismatch repair (MMR) genes cause Lynch syndrome (LS). LS is an inherited disease, and an
important consequence of MMR deficiency is microsatellite instability (MSI) phenotype. MSI phenotype influences the efficacy of
5 fluorouracil (5-FU) chemotherapy. Reproducible, cost effective, and easy to perform laboratory tests are required to include MSI
detection in routine laboratory practice. Evaluation of CAT25 as monomorphic short tandem repeat sequence enables CAT25 to
be an efficient screening tool among hereditary nonpolyposis colorectal cancer (HNPCC) patients compared with other methods
used currently.
Methods: Based on Amsterdam II criteria, 31 patients in 31 families were shortlisted from a total number of 1,659 colorectal
cancer patients. MSI status was examined in these patients using CAT25 and a commercially available Promega MSI five-marker-
based detection system as well as immunohistochemical (IHC) staining of four important MMR proteins. Patients were scored as
high microsatellite instable (MSI-H), low (MSI-L), or stable (MSS). MSI status determined by CAT25 single mononucleotide
marker was compared with that of five mononucleotide markers, Promega commercial kit, and IHC method.
Results: MMR protein deficiency was observed on 7/31 probands using IHC methodology and 6/31 categorized as MSI-H using
commercial kit or CAT25 single marker. The sensitivity and specificity of the CAT25 single marker were the same as those detected
by five-marker Promega commercial kit in our patients.
Conclusions: Based on our results, the performance of the CAT25 single mononucleotide marker for MSI status determination in
our HNPCC patients is the same as that of the five-marker-based commercial kit.
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Introduction
Colorectal cancer (CRC) is one of the most common types of
cancer  worldwide1.  Sporadic  CRC  is  the  main  form  of  the
disease,  comprising  greater  than  90%  of  all  CRC  cases.
Familial adenomatous polyposis (FAP) and Lynch syndrome
(LS) or hereditary nonpolyposis  colorectal  cancer (HNPCC)
are  the  most  prevalent  hereditary  forms  of  CRC2.  These
hereditary  forms  are  inherited  in  an  autosomal  dominant
manner  with  50%  risk  of  transmission  to  the  offspring3.
Differentiation  of  sporadic  CRCs  from  the  hereditary  forms
is usually accomplished based on the available criterion, such
as  Amsterdam  or  Bethesda.  However,  categorization  based
on the  abovementioned criteria  must  be  confirmed through
an  appropriate  genetic  testing4.  Germline  mutations  within
the  mismatch  repair  (MMR)  genes  can  lead  to  LS  (OMIM
120435)  or  HNPCC5.  MMR  gene  mutations  result  in
impaired base MMR error during DNA replication, allowing
accumulation of mutations in the DNA. Risk of other cancers
(except CRCs),  such as ovary,  gastrointestinal,  and breast,  is
also  rising  considerably  in  HNPCC  patients  who  have
mutations in MMR genes6. Microsatellite instability (MSI) as
a  phenomenon  is  frequently  observed  in  HNPCC  patients,
and approximately 10% is affected by sporadic CRC because
of the inherent pitfall of DNA polymerase in replicating short
tandem  repeat  (STR)  DNA  sequences,  especially
mononucleotide  repeats7.  Under  these  circumstances,  new
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mononucleotide  STR  alleles  can  be  produced  because  of
unrepaired  expansion  or  contraction  of  the  existing  STRs,
which  is  called  MSI  phenotype.  This  phenomenon  is
currently  used  for  screening  and  confirmation  of  LS  and
differentiates  them  from  those  affected  by  sporadic  CRC8.
Immunohistochemical  (IHC)  detection  of  MLH1,  MSH2,
MSH6,  or  PMS2  MMR  protein  deficiency9,10  or  by
polymerase chain reaction (PCR)-based methods are used for
MSI  testing11.  MSI-H  tumors  are  predominantly  located  in
the  right  or  proximal  colon  and  are  characterized  by  poor
differentiation,  mucinous  histology,  and  lymphocytic
infiltration.  Based  on  the  available  evidence,  this
pathologically  unique  subset  of  CRCs  exhibited  significant
differences in clinical  behavior.  Meanwhile,  the prognosis  of
MSI-H tumors is  discreetly better than that of microsatellite
stable  (MSS)  or  MSI-low  (MSI-L)  tumors12.  However,  they
seem  to  obtain  no  benefit  from  adjuvant  5-fluorouracil  (5-
FU) chemotherapy. This 5-FU resistance is proposed to stem
from  the  incorporation  of  5-FU  metabolites  into  DNA
instead of inhibiting its effective target, which is thymidylate
synthase13.  Therefore,  MSI  typing  is  likely  to  become  a
routine diagnostic procedure in all CRC patients; however, at
present,  it  is  usually  applied  to  patients  suspected  for
hereditary  CRC  prescreened  by  Amsterdam  or  Bethesda
criteria14.  To  date,  the  standard  testing  procedure  for  the
PCR-based  detection  of  MSI  status  recommended  by  the
National  Cancer  Institute/International  Collaborative
Group/HNPCC (NCI/ICG-HNPCC)  is  five  mononucleotide
markers for tumor and nontumor adjacent normal tissues. At
present,  the  most  frequently  used  PCR-based  commercial
MSI  testing  kit  is  a  five  mononucleotide  marker  kit
developed  by  Promega,  Madison,  WI4.  Five  quasimono-
morphic  mononucleotide  markers,  including  NR-21,  BAT-
25,  MONO-27,  NR-24,  BAT-26,  and  2  pentanucleotide
repeats, involving penta C and penta D are used in this kit15.
However, this technique is expensive, laborious, and difficult
to optimize16. Much research has been conducted to evaluate
the  few  number  of  STR  markers  in  MSI  testing  without
compromising the sensitivity and specificity of the test17-20.
Here, we aimed to evaluate the sensitivity and specificity of
a new MSI marker, the T25 mononucleotide repeat of the
caspase  2  gene  (CAT25).  Thirty-one  families  sorted
according to the Amsterdam II criteria were included in this
work. DNA was extracted from the tumor as well as normal
adjacent  formalin-fixed  paraffin  embedded  tissues  using
QIAamp DNA FFPE Tissue Kit (Qiagen, Germany). All DNA
samples were subjected to MSI detection using the Promega
MSI testing system (MSI Analysis System, Version 1.2) and
CAT25 in the house-developed protocol. In addition, IHC
was performed on the tissue sections cut out from the same
samples used for DNA extraction.
Materials and methods
Subjects
The study was approved by the Ethical Committee of Isfahan
University  of  Medical  Sciences.  All  patients  provided
informed consent. All patients diagnosed with CRC between
2000  and  2013  and  registered  at  Poursina  Hakim  Research
Center and Clinic,  Isfahan, Iran were included in this study.
The  total  number  of  patients  screened  in  this  study  was
1, 659. Finally, 31 families were selected based on Amsterdam
II criteria for HNPCC. Each of the following criteria must be
fulfilled:  three  or  more  relatives  with  an  associated  cancer,
two  or  more  successive  generations  affected,  one  or  more
relatives diagnosed before the age of 50 years, and one should
be a first-degree relative of the other two. Paraffin-embedded
formalin-fixed  tissue  blocks  were  obtained  from  each
proband to evaluate MSI status by either IHC or PCR-based
techniques  using  multiplex  commercially  available  MSI
detection  kit  (Promega,  USA)  as  well  as  our  in-house
developed  monoplex  CAT25  marker.  FAP  cases  were
excluded.
MSI status by immunohistochemistry
All  tissue  blocks  were  sectioned and subjected  to  IHC study
to  determine  the  MMR  status  as  previously  described9,10
using standard techniques21.
MSI status by PCR-based methods
A  commercial  kit  from  Promega  (MSI  Analysis  System,
Version 1.2)  was  used for  MSI  typing.  Five  mononucleotide
markers  and  two  pentanucleotide  markers  (penta  C  and
penta  D)  are  included  for  probable  cross  contamination  or
samples’ mix up detection. Three categories of MSI status are
observed  by  using  Promega  kit,  MSI-H,  MSI-L,  and  MSS
showing  more  or  less  than  30%  instabilities  of  the  markers.
Primer-BLAST  software  was  used  to  design  primers  for
CAT25  locus.  Forward  primer  sequence  is  5′-CCTAG
AAACCTTTATCCCTGCTT-3′  and  reverse  primer  sequence
is  5′-GAGCTTGCAGTGAGCTGAGA-3′.  PCR  primers  were
labeled  at  the  5′  end  with  Cy5  for  the  subsequent  analysis
using  ALFexpress  DNA  sequencer  (Amersham  Pharmasia
Biotech). Up to 30 ng of DNA, 0.2 mmol of deoxynucleotide
triphosphates,  10  pmol  of  each  primer,  1×  PCR  buffer,  1.5
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mmol MgCl2,  and 0.5 units Taq DNA polymerase were used
for PCR reaction. The total volume reached 25 μL. The PCR
stages  are  as  follows:  initial  denaturation  in  5  min  at  94°C
and  then  32  cycles  of  denaturation  at  94°C,  annealing  at
59°C,  extension  at  72°C  for  30  s  for  each  condition,  and  a
final extension at 72°C for 5 min. For fragment analysis, 3 μL
of appropriately diluted PCR products was mixed with 1.5 μL
of  formamide  and  1.5  μL of  DNA loading  dye  (Fermentas).
After  completion  of  the  run,  DNA  fragments  were  analyzed
using  AlleleLink  software  provided  by  the  manufacturer.
Statistical  analyses  of  the  obtained  data  were  performed  by
SPSS  16  software  package  (SPSS  Inc.,  Chicago,  IL,  USA).
Comparison of diagnostic sensitivity/specificity of the marker
CAT25 ROC analysis was also conducted.
Results
Among the 1,659 CRC-affected patients based on Amsterdam
II  criteria,  31  probands  representative  of  31  families  were
selected  in  this  study.  The  medical  records  of  all  31  families
included in this  study were examined carefully  and asked to
complete  a  comprehensive  questionnaire.  Based  on the  data
regarding  cancer  prevalence  extracted  from  the  patients’
records  and  questionnaires,  a  total  of  186  individuals  from
these  31  families  were  determined  to  be  affected  by  various
cancers.  Eighty-six  of  them  showed  CRC  (46.2%).  The
remaining  100  patients  (53.8%)  exhibited  extracolonic
cancers.
Immunohistochemistry results
Overall,  loss  of  MMR  expression  was  observed  in
7/31probands (22.6%). An example of MSH2 expression in a
patient  with  MMR  is  shown  in  Figure  1.  Both  MSH6  and
MSH2 were negative on 4/7 (57.1%). MLH1 and PMS2 were
negative on 2/7 (28.6%) and in one case. MSH6 was defective
(14.3%).  As  we  expected,  only  MSH6-deficient  tumor  was
MSS  (Figure  2).  Data  from  all  patients  are  summarized  in
Tables 1 and 2.
 
Figure  1     MSH2  expression  in  MMR-proficient  sample  (IHC
staining, 40×).
 
Figure 2   Promega system results and IHC for MSH6-deficient patient. Stability in tumor tissue (A) compared with normal tissue (B). IHC
staining demonstrating loss of MSH6 expression in the patient (C) (10 ×).
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MSI analysis using promega MSI detection
system
Nine  out  of  31  patients  (29%)  showed  MSI  in  their  tumor
tissues  [six  patients  (19.4%)  with  MSI-H].  The  first  marker
showed that  the  highest  instability  was  BAT-26,  followed by
7/31  MSI  tumors  (22.6%).  Then,  both  BAT-25  and  NR-24
markers  showed  instability  on  6/31  (19.3%).  Two  markers
were  found  unstable  in  5/31  (MONO-27  and  NR-21)
(16.1%)  tumors.  The  4/6  (66.6%)  CRC  patients  showed
instability in all  markers of the kit.  Another showed stability
only  in  one  marker  (MONO-27).  The  other  exhibited  two
unstable  markers  (BAT-26 and NR-24)  (Figure  3).  Figure  4
shows  the  example  of  fragment  analysis  results  of  the  PCR
Table 1   Primary tumor site in patients according to their MMR status detected by IHC
Tumor site
MMR-proficient families
 
MMR-deficient families
Frequency Percent Frequency Percent
Cecum 3 12.5 1 14.3
Ascending colon 2 8.3 2 28.6
Transverse colon 0 0.0 1 14.3
Descending colon 0 0.0 2 28.6
Sigmoid colon 8 33.3 1 14.3
Rectum 10 41.7 0 0.0
Unknown 1 4.2 0 0.0
Total 24 100.0 7 100.0
Table 2   Cancer type frequency according to their MMR status detected by IHC
Cancer type
MMR proficient
 
MMR deficient
Sum
Frequency Percent Frequency Percent
CRC 55 39.3
 
31 67.4 86
GC 14 10.0 4 8.7 18
Lung 12 8.6 2 4.3 14
Breast 11 7.9 1 2.2 12
Brain 9 6.4 0 0.0 9
HBC 7 5.0 2 4.3 9
Intestine 6 4.3 0 0.0 6
Prostate 4 2.9 2 4.3 6
Uterus 4 2.9 1 2.2 5
Skin 3 2.1 0 0.0 3
HP 3 2.1 3 6.5 6
Bladder 3 2.1 0 0.0 3
Thyroid 2 1.4 0 0.0 2
Testis 2 1.4 0 0.0 2
Bone 2 1.4 0 0.0 2
Kidney 1 0.7 0 0.0 1
Pancreas 1 0.7 0 0.0 1
Nasopharynx 1 0.7 0 0.0 1
Total 140 100 46 100 186
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product  of  the  samples.  The average age  was  44.7,  51.7,  and
36.0 years at the time of diagnosis of MSS, MSI-L, and MSI-
H probands, respectively (P=0.123).
The most frequent tumor sites were rectosigmoid (72.8%),
rectum (66.7%), and right colon (50.0%) in CRC probands
with MSS, MSI-L, and MSI-H phenotype, respectively. As we
expected, 70% of the CRC tumors were located in the right
side of the splenic flexure for MSI-H tumors. However, it was
18.6% for MSS tumors. The survival period of the probands
was  6.1,  2.0,  and  5.8  years  for  MSS,  MSI-L,  and  MSI-H
groups of the probands, respectively (P=0.341).
The average number of  patients  diagnosed with cancer
among MSS, MSI-L, and MSI-H groups from the HNPCC
 
Figure 3   Number of tumors that were unstable or stable for each
of  6  markers  (5  markers  in  Promega  kit  plus  a  single  CAT25
marker). For CAT25, 25 patients are grouped in MSS (orange) and
6 in MSI-H (blue).
 
Figure 4   Capillary electrophoresis results from the Promega system. A panel consisting of five mononucleotide marker was used for MSI
determination via multiplex PCR. X axis is the size in bases. Y axis is the fluorescence intensity. Green peaks are amplification products from
microsatellite loci, including three of five markers shown here (NR21, BAT25, and MONO27). Note the shift in the size (bases) of the
amplification products in the tumor specimen compared with normal ones. An example of one shifted locus is demonstrated in the tumor
sample (B) compared with normal one (A).
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families was 5.4, 7.7, and 6.0 patients per family, respectively
(P=0.12). In addition, on average, 2.2, 3.3, and 4.7 patients
per  family  existed  in  CRC-affected  members  among  our
HNPCC  families  in  MSS,  MSI-L,  and  MSI-H  groups,
respectively (P=0.014). Meanwhile, the average number of
affected  members  by  extracolonic  cancers  in  these  three
groups was 3.2, 4.3, and 1.3 patients per family (P=0.045).
Among the MSS, MSI-L, and MSI-H groups of these families,
the proportion of CRC patients to all  cancer patients was
40.3%,  41.7%,  and  65.1%,  respectively.  The  stomach
(18.3%), lung (15.5%), and breast (11.3%) were the most
commonly involved organs in the MSS group of the studied
families  in  extracolonic  cancers.  The  lung  (28.9%)  and
stomach (23.7%) in males and the breast (24.2%) and brain
(15.2%)  among  the  females  were  the  most  prevalently
involved organs in extracolonic cancers. The most common
involved  organs  were  the  breast  (21.4%)  and  brain  and
hepatobiliary  tract  (14.3%)  in  MSI-L  families  and  the
stomach (26.7%) and hematopoietic system (20.0%) in MSI-
H families. The most prevalently involved organs in MSI-H
families (except CRCs) among the males were the stomach
(25.0%) and hematopoietic system (33.3%). In females, the
majority of cases were CRC (84.2%) and the breast, uterus,
and hepatobiliary tract (33.3% for all three cancers). The 8,
10, and 18 different organs were affected within MSI-H, MSI-
L,  and  MSS  families,  respectively.  The  most  common
pathological  phenotype in  MSS (31.8%) and MSI-L CRC
tumors (66.7%) was “well differentiated adenocarcinoma”,
whereas “moderately differentiated adenocarcinoma” was in
MSI-H CRC tumors (50.0%). Moreover, more than half of
the MSS, MSI-L, and MSI-H CRC tumors of the probands
have been diagnosed in late pathological TNM stages (stage
III  or  IV)  (63.6%,  100%,  and  83.3%,  respectively).  The
proportion of the deceased probands among the MSS, MSI-L,
and MSI-H groups was 31.8%, 100%, and 33.3%, respectively.
Sensitivity and specificity for CAT25 marker
CAT25  was  unstable  in  all  six  patients  with  MSI-H  (100%)
but  showed  stability  in  MSS  and  MSI-L  patients.  Sensitivity
and  specificity  of  CAT25  marker  compared  with  Promega
were  100%  (Figure  5).  All  MSI-H  tumors  were  correctly
identified as MSI-H by CAT25 marker. No MSS tumors were
incorrectly identified as MSI-H by the marker compared with
Promega system.
Discussion
In  this  study,  MSI,  IHC,  and  different  clinical  criteria  were
analyzed  for  predicting  and  detecting  loss  of  expression  of
MMR  genes  to  differentiate  the  families  with  hereditary,
HNPCC,  and  sporadic  CRC.  To  accomplish  this  task,  31
families  for  which  a  tumor  sample  was  available  were
evaluated.  All  the  31  patients  fulfilled  the  Amsterdam  II
criteria.  MSH6  and  PMS2  bind  to  MSH2  and  MLH1,
respectively. Moreover, they expressed with their partner but
not alone22. Therefore, in the IHC results as expected, loss of
MSH6 and MSH2 expression were both detected in 57.1% of
the patients. Meanwhile, loss of PMS2 and MLH1 expression
were  together  detected  in  28.6%  of  the  patients.  CRCs  and
associated  cancers  in  LS/HNPCC  families  are  reported  to
occur  in  younger  age  than  the  general  population23.
Furthermore, the results showed that compared with MMR-
proficient  CRCs  among  LS  families,  MMR-deficient  tumors
 
Figure 5     MSI assay by single marker (CAT25) showing instability in tumor tissue (bottom) compared with normal tissue (top). The
amplified products were separated by ALF express fragment analysis. Comparison of peak patterns with a shift in PCR product size of the
tumor with normal ones represents instability. The arrows represent shifts in base pairs compared with normal tissue. The 22 and 23 lines
are normal and tumoral tissues in one patient. The 24 and 25 lines are in another one. One example of MSS status detected by CAT25
marker is shown (right).
Cancer Biol Med Vol 14, No 2 May 2017 147
occurred  in  younger  patients  similar  to  that  in  MSI  cases24.
Deficiency in the DNA MMR pathway can lead to MSI. DNA
MMR  function  is  lost  because  of  biallelic  inactivation
(Knudson  two  hit  theory)25  in  one  of  the  genes  involved  in
the DNA MMR pathway (MSH2, MLH1, MSH6, PMS2, and
PMS1)  in  HNPCC26.  Methylation  of  the  MLH1  gene  is  an
alternative cause of MMR deficiency in sporadic CRCs27. MSI
detection  can  be  useful  for  identifying  probands  in  families
with  HNPCC  because  MSI  status  can  be  used  in  clinical
management  and  also  in  making  right  decision  about
treatment  approaches28.  Different  numbers  of  mononu-
cleotide  STRs  have  been  used  for  MSI  status  determination
and categorization of CRC patients into two main categories,
namely, MSS and MSI high. An additional category, although
less  important,  is  MSI  low8.  The  methods  and  criteria  to
determine  MSI  in  CRC  have  constantly  evolved  because  its
initial  discovery  was  more  than  a  decade  ago.  Therefore,
some investigations have been performed to date  to identify
an easy to perform and cost-effective assay for MSI status. A
panel  of  markers  for  detection  defects  within  the  MMR
system  (three  dinucleotides  and  two  mononucleotide
repeats) was suggested by NCI; however, the usefulness of the
panel is argued because of the low sensitivity of dinucleotide
repeats14,27,29.  To  choose  the  use  of  current  MSI  assays  is
difficult  because  of  economical  and  application  issues  in
routine  laboratory  workflow30.  We  provide  evidence  that  a
single  PCR  assay  with  only  one  marker  should  be  the
recommended  method  for  MSI  evaluation  in  clinical  and
research laboratories.
The results presented here support the three important
conclusions as follows:
The feature of LS includes cancers occurring at younger
ages than that in the general population31,32. In addition, the
average age of proficient probands’ group was younger than
that  of  MMR-deficient  probands’  group.  Although  LS  is
determined as a single condition, the clinical phenotypes can
vary significantly depending upon the gene involved32. We
showed in this study that 57.1 of CRC patients with MMR
deficiency were detected proximal to the splenic flexure (P<
0.01).  Furthermore,  CRCs  are  more  common than other
types of cancers among MMR-deficient families.
High-level  MSI  results  were  concordant  with  MMR
protein  loss  results  in  MMR defective  samples.  However,
none of the three MSI-L tumors were MMR deficient.  All
MSI-H cases were in concordance with the MMR protein
defects but in MSI-L cases were not. The significance of low-
level  DNA  microsatellite  instability  (MSI-L)  is  not  well
understood. In MSI-L, all CRCs were relatively unstable if
enough  markers  were  used  in  the  MSI  assay.  Therefore,
detecting MSI-L by more markers, such as Promega kit but
not in single marker test, e.g., CAT25 marker that we tested
here, is possible. To include MSI-L to MSS category may be
beneficial  because  of  their  similar  response  to  che-
motherapy33,34. The chromosomal instability carcinogenesis
pathway is the cause of MSI-L tumors similar to MSS tumors
but  unlike  MSI-H  tumors35.  High  frequency  of  K-RAS
mutations  in  MSI-L  cancers  and  methylat ion  of
methylguanine  transferase  in  MSI-L  tumors  have  been
reported in contrast to MSI-H where more mutations occur
in  MMR  pathway;  however,  this  finding  is  not  clear  in
others36-39.  MSI-H  tumors  exhibit  a  distinct  clinicopa-
thological phenotype in contrast to MSI-L or MSS tumors,
including poorly differentiated, right-sided, and mucinous,
extendible  growth  pattern  and  tumor-infi ltrating
lymphocytes40. This finding is consistent with our results that
the most common pathological phenotype in MSS (31.8%)
and MSI-L CRC tumors (66.7%) was “well-differentiated
adenocarcinoma”,  whereas  that  in  MSI-H  CRC  tumors
(50.0%) was “moderate-differentiated adenocarcinoma”.
To find the best marker as a biomarker tool for diagnosis,
many investigations have been conducted on MSI markers
because MSI is an important marker to screen for HNPCC as
well  as  a  prognostic  and  predictive  marker  for  sporadic
colorectal cancer41-43. Promega kit offered a highly sensitive
and specific method in the detection of MSI. However, it is
still time consuming and expensive. Therefore, we suggest
using single mononucleotide marker, such as CAT25, that
can properly detect all the MMR-defective cases alone but
without any false positivity in contrast to BAT-26.
Conclusions
A  simplified  assay  for  MSI  is  tested  in  this  study.  The  one
mononucleotide  marker  (CAT25)  exhibited  high  specificity
and sensitivity for identifying tumors with MMR deficiency.
The  results  of  studies  on  distinct  markers  in  different
populations  are  different.  Therefore,  assessing  markers  in
different ethnics to confirm that the results of these markers
are  similar  to  that  in  different  countries  with  actually
different  ethnic  backgrounds  is  necessary.  The  results  above
lead  us  to  conclude  that  MSI  and  IHC  results  were  in
concordance  with  each other.  However,  MSI  typing  is  more
accurate  than  IHC.  The  results  provided  for  CAT25  marker
suggest that MSI testing for LS would be a cost-effective and
convenient  method by  using  only  one  marker,  or  at  least,  it
can be included in panel to detect MSI status. Using a single
CAT25 marker is fast, easy to perform, cost effective with the
least  optimization  and  technically  challenging  involvement.
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Sensitivity and specificity data on CAT25 single marker show
the success of strategy for excluding the majority of MSS cases.
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